Skip to main content
SpringerLink
Log in

Patterns of oncogene activation in human neuroblastoma cells

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Human neuroblastoma is the most frequent solid tumor in children. Recent studies suggest that a multiplicity of genomic alterations contributes to neuroblastoma, the most frequent and well studied being deletion of the short arm of chromosome 1 and amplification of N-MYC. We here present and discuss different patterns of oncogene activation including, amplification of N-MYC, duplication of N-MYC and amplification of MDM2.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Schwab M, Corvi R, Amler L: MYCN oncogene amplification: a consequence of genomic instability in human neuroblastoma. The Neuroscientist 1, 5: 277–285, 1995

    Google Scholar 

  2. Alitalo K, Schwab M: Oncogene amplification in tumor cells. Ad Cancer Res 47: 235–281, 1986

    Google Scholar 

  3. Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, Brodeur G, Goldstein, M, Trent J: Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumor. Nature (London) 305: 245–248, 1983

    Google Scholar 

  4. Berthold F: Neuroblastoma: tumor biology and therapy. In Pochedly, C. (ed) Critical reviews in oncogenesis. CRC Press, Inc., Boca Raton, 1990, pp. 1–27

    Google Scholar 

  5. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM: Amplification of N-MYC in untreated human neuroblastomas correlates with advanced disease stage. Science 224: 1121–1124, 1984

    Google Scholar 

  6. Kohl N, Kanda K, Schreck PR, Bruns G, Latt S, Gilbert F, Alt F: Transposition and amplification of oncogene-related sequences in human neuroblastomas. Cell 35: 359–367, 1983

    Google Scholar 

  7. Schwab M, Varmus HE, Bishop JM, Grzeschik K-H, Naylor S, Sakaguchi A, Brodeur GM, Trent J: Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc. Nature (London) 308: 288–291, 1984

    Google Scholar 

  8. Corvi R, Savelyeva L, Amler L, Handgretinger R, Schwab M: Cytogenetic evolution of MDM2 and MYCN amplification in the neuroblastoma LS tumour and its cell line. Eur J of Cancer 31A, 4: 520–523, 1995

    Google Scholar 

  9. Corvi R, Amler LC, Savelyeva L, Gehring M, Schwab M: MYCN is retained in single copy at chromosome 2 band p23–24 during amplification in human neuroblastoma cells. Proc Natl Acad Sci US 91: 5523–5527, 1994

    Google Scholar 

  10. Amler LC, Schwab M: Amplified N-MYC in human neuroblastoma cells is often arranged as clustered tandem repeats of differently recombined DNA. Mol Cell Biol 9: 4903–4913, 1989

    Google Scholar 

  11. Cziepluch C, Wenzel A, Schürmann J, Schwab M: Activation of gene transcription by the amino terminus of the N-MYC protein does not require association with the protein encoded by the retinoblastoma supressor gene RB1. Oncogene 8: 2833–2838, 1993

    Google Scholar 

  12. Wenzel A, Schwab M: The mycN/max protein complex in neuroblastoma. Short review. Eur J Cancer 31A, 4: 516–519, 1995

    Google Scholar 

  13. Corvi R, Savelyeva L, Schwab M: Duplication of N-MYC at its resident site 2p24 may be a mechanism of activation alternative to amplification in human neuroblastoma cells. Cancer Res 55: 3471–3474, 1995

    Google Scholar 

  14. Savelyeva L, Corvi R, Schwab M: Translocation involving 1p and 17q is a reccurrent genetic alteration of human neuroblastoma cells. Am J Hum Genet 55: 334–340, 1994

    Google Scholar 

  15. Wenzel A, Cziepluch C, Hamann U, Schürmann J, Schwab M: The N-MYC oncoprotein is associated in vivo with the phosphoprotein Max(p20/22) in neuroblastoma cells. EMBO J 10: 3703–3712, 1991

    Google Scholar 

  16. Wada RK, Seeger RC. Brodeur GM, Einhorn PA, Rayner BS, Tomayko MM, Reynolds P: Human neuroblastoma cell lines that express N-MYC without gene amplification. Cancer 72: 3346–3354, 1993

    Google Scholar 

  17. Cohn S, Salwen H, Quasney MW, Ikegaki N, Cowan JM, Herst CV, Kennet RH, Rosen ST, DiGiuseppe JA, Brodeur GM: Prolonged N-MYC protein half-life in a neuroblastoma cell line lacking N-MYC amplification. Oncogene 5: 1821–1827, 1990

    Google Scholar 

  18. Trask BJ, Hamlin JL: Early dihydrofolate reductase gene amplification events in CHO cells usually occur on the same chromosome arm as the original locus. Genes & Dev 3: 1913–1925, 1989

    Google Scholar 

  19. Corvi R, Savelyeva L, Breit S, Wenzel A, Handgretinger R, Barak J, Oren M, Amler L, Schwab M: Non-syntenic amplification of MDM2 and MYCN in human neuroblastomas. Oncogene 10: 1081–1086, 1995

    Google Scholar 

  20. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80–83, 1992

    Google Scholar 

  21. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson R, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B: Mutations in p53 gene occur in diverse human tumor types. Nature 342: 705–708, 1989

    Google Scholar 

  22. Komura H, Hayashi Y, Kawamura M, Hayashi K, Kaneko Y, Kamoshita S, Hanada R, Yamamoto K, Hongo T, Yamada M, Tsuchida Y: Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas. Cancer Res 53: 5284–5288, 1993

    Google Scholar 

  23. Ohgaki H, Eibl M, Schwab M, Reichel M, Mariani L, Gehring M, Peterson I, Höll T, Wiestler O, Kleihues P: Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system. Mol Carcinogenesis 8: 74–80, 1993

    Google Scholar 

  24. Vogan K, Bernstein M, Leclerc J-M, Brisson L, Brossard J, Brodeur GM, Pelletier J, Gros P: Absence of p53 gene mutations in primary neuroblastomas. Cancer Res 53: 5269–5273, 1993

    Google Scholar 

  25. Moll U, LaQuaglia M, Beénard J, Riou G: Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci USA 92: 4407–4411, 1995

    Google Scholar 

  26. Xiao Z, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR, Livingston DM: Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375: 694–697, 1995

    Google Scholar 

  27. Rustgy AK, Dyson N, Bernards R: Amino-terminal domains of C-MYC and N-MYC protein mediate binding to the neuroblastoma gene product. Nature 352: 541–544, 1991

    Google Scholar 

  28. Weith A, Martinssons T, Cziepluch C, Brüderlein S, Amler LC, Berthold F, Schwab M: Neuroblastoma consensus deletion maps to 1p36.1–2. Genes Chrom Cancer 1: 159–166, 1989

    Google Scholar 

  29. Gehring M, Berthold F, Edler L, Schwab M, Amler LC: 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma. Cancer Res 1995 (in press)

  30. Versteeg R, Caron H, Cheng NC, van der Drift P, Slater R, Westerveld A, Voute PA, Delattre O, Laureys G, Van Roy N, Speleman F: 1p36: Every subband a suppressor? Eur J Cancer 31A, 4: 510–515, 1995

    Google Scholar 

  31. Fong CT, White PS, Peterson K, Sapienza C, Cavenee WK, Kern SE, Vogelstein B, Cantor AB, Look AT, Brodeur GM: Loss of heterozygosity for chromosome 1 or 14 defines subsets of advanced neuroblastomas. Cancer Res 52: 1780–1785, 1992

    Google Scholar 

  32. Christiansen H, Lampert F: Tumor cytogenetics and prognosis in neuroblastoma. Monatsschr Kinderheilkd 137: 666–671, 1989

    Google Scholar 

  33. Caron H, van Sluis P, de Kraker J, Boökkerink J, Egeler M, Laureys G, Slater R, Westerveld A, Voute PA, Versteeg R: Allelic loss of chromosome 1p identifies neuroblastoma patients at high risk of an unfavorable outcome. (submitted)

  34. Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos G, Healey JH: MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 53: 16–18, 1993

    Google Scholar 

  35. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B: p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 53: 2231–2234, 1993

    Google Scholar 

  36. Nilbert LM, Rydholm A, Willeén H, Mitelman F. Mandahl N: MDM2 gene amplification correlates with ring chromosomes in soft tissue tumors. Genes Chromosomes Cancer 9: 261–265, 1994

    Google Scholar 

  37. Pedeutour F, Suijkerbuijk RF, Forus A, van Gaal J, van der Klundert W, Coindre J-M, Nicolo G, Collin F, van Haelst U, Huffermann K, Turc-Carel C: Complex composition and co-amplification of SASand MDM2in ring and giant rod marker chromosomes in well-differentiated liposarcoma. Genes Chromosomes Cancer 10: 85–94, 1994

    Google Scholar 

  38. Reifenberger G, Kiu L, Ichimura K, Schmidt EE, Collings VP: Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53: 2736–2739, 1993

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Deutsches Krebsforschungszentrum, Abteilung Zytogenetik, Im Neuenheimer Feld 280, D-69120, Heidelberg, Germany

    Raffaella Corvi, Larissa Savelyeva & Manfred Schwab

Authors
  1. Raffaella Corvi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Larissa Savelyeva
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Manfred Schwab
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Corvi, R., Savelyeva, L. & Schwab, M. Patterns of oncogene activation in human neuroblastoma cells. J Neurooncol 31, 25–31 (1997). https://doi.org/10.1023/A:1005721027709

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1005721027709

Search

Navigation